AU2010236734B2 - 5-HT4 receptor agonist compounds for treatment of cognitive disorders - Google Patents
5-HT4 receptor agonist compounds for treatment of cognitive disorders Download PDFInfo
- Publication number
- AU2010236734B2 AU2010236734B2 AU2010236734A AU2010236734A AU2010236734B2 AU 2010236734 B2 AU2010236734 B2 AU 2010236734B2 AU 2010236734 A AU2010236734 A AU 2010236734A AU 2010236734 A AU2010236734 A AU 2010236734A AU 2010236734 B2 AU2010236734 B2 AU 2010236734B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- patient
- scopolamine
- disease
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16874109P | 2009-04-13 | 2009-04-13 | |
| US61/168,741 | 2009-04-13 | ||
| US29255910P | 2010-01-06 | 2010-01-06 | |
| US61/292,559 | 2010-01-06 | ||
| PCT/US2010/030760 WO2010120695A2 (en) | 2009-04-13 | 2010-04-12 | 5-ht4 receptor agonist compounds for treatment of cognitive disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2010236734A1 AU2010236734A1 (en) | 2011-11-03 |
| AU2010236734A8 AU2010236734A8 (en) | 2012-02-16 |
| AU2010236734B2 true AU2010236734B2 (en) | 2015-06-11 |
Family
ID=42237213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2010236734A Ceased AU2010236734B2 (en) | 2009-04-13 | 2010-04-12 | 5-HT4 receptor agonist compounds for treatment of cognitive disorders |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8404711B2 (https=) |
| EP (1) | EP2419104B1 (https=) |
| JP (1) | JP2012523437A (https=) |
| KR (1) | KR20120017421A (https=) |
| CN (2) | CN102395371A (https=) |
| AU (1) | AU2010236734B2 (https=) |
| BR (1) | BRPI1013777A8 (https=) |
| CA (1) | CA2758321A1 (https=) |
| CY (1) | CY1119800T1 (https=) |
| DK (1) | DK2419104T3 (https=) |
| ES (1) | ES2654930T3 (https=) |
| HR (1) | HRP20180018T1 (https=) |
| HU (1) | HUE038141T2 (https=) |
| IL (1) | IL215660A0 (https=) |
| LT (1) | LT2419104T (https=) |
| MX (1) | MX2011010782A (https=) |
| NO (1) | NO2419104T3 (https=) |
| PL (1) | PL2419104T3 (https=) |
| PT (1) | PT2419104T (https=) |
| RU (1) | RU2569056C2 (https=) |
| SI (1) | SI2419104T1 (https=) |
| SM (1) | SMT201800036T1 (https=) |
| WO (1) | WO2010120695A2 (https=) |
| ZA (1) | ZA201107490B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| LT2889033T (lt) | 2008-11-19 | 2018-07-10 | Forum Pharmaceuticals Inc. | Šizofrenijos negatyvių simptomų gydymas (r)-7-chlor-n-(chinuklidin-3-il)benzo[b]tiofen-2-karboksamidu ir jo farmaciniu požiūriu priimtinomis druskomis |
| JP5808319B2 (ja) * | 2009-05-11 | 2015-11-10 | フォルム ファーマシューティカルズ、インコーポレイテッド | アセチルコリンエステラーゼ阻害剤と組み合わせた特定のα７ニコチン酸受容体を用いた認知障害の治療 |
| PE20170923A1 (es) | 2010-05-17 | 2017-07-12 | Forum Pharmaceuticals Inc | Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida monohidratado |
| EP3461481A1 (en) | 2012-05-08 | 2019-04-03 | Forum Pharmaceuticals Inc. | Methods of maintaining, treating or improving cognitive function |
| US10874701B2 (en) | 2012-08-16 | 2020-12-29 | University-Industry Cooperation Group Of Kyung Hee University | Lactic acid bacteria capable of preventing and/or treating senescence and dementia |
| JP6009080B2 (ja) | 2012-08-16 | 2016-10-19 | ユニバーシティ−インダストリー コオペレーション グループ オブ キョン ヒ ユニバーシティＵｎｉｖｅｒｓｉｔｙ−Ｉｎｄｕｓｔｒｙ Ｃｏｏｐｅｒａｔｉｏｎ Ｇｒｏｕｐ Ｏｆ Ｋｙｕｎｇ Ｈｅｅ Ｕｎｉｖｅｒｓｉｔｙ | 老化及び認知症の予防及び／または治療活性を有する乳酸菌 |
| BR112019001145A2 (pt) | 2017-05-24 | 2019-04-30 | H. Lundbeck A/S | combinação de um antagonista do receptor 5-ht6 e de um inibidor de acetilcolinesterase para uso no tratamento da doença de alzheimer em uma subpopulação de pacientes portadores de alelos de apoe4 |
| KR20200010211A (ko) | 2017-06-01 | 2020-01-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Pde9 저해제를 포함하는 약제학적 조성물 |
| KR20190137936A (ko) | 2017-06-02 | 2019-12-11 | 후지필름 도야마 케미컬 가부시키가이샤 | 뇌 위축 예방 또는 치료제 |
| BR112020000482A2 (pt) | 2017-07-31 | 2020-07-21 | Theravance Biopharma R&D Ip, Llc | métodos de tratamento de sintomas de gastroparesia usando velusetrag |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006108127A2 (en) * | 2005-04-06 | 2006-10-12 | Theravance, Inc. | Crystalline form of a quinolinone-carboxamide compound |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2133078A1 (en) * | 2000-03-03 | 2009-12-16 | Eisai R&D Management Co., Ltd. | Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments |
| TWI351282B (en) * | 2004-04-07 | 2011-11-01 | Theravance Inc | Quinolinone-carboxamide compounds as 5-ht4 recepto |
| US7598265B2 (en) * | 2004-09-30 | 2009-10-06 | Epix Delaware, Inc. | Compositions and methods for treating CNS disorders |
| MY147756A (en) * | 2005-05-25 | 2013-01-15 | Theravance Inc | Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists |
-
2010
- 2010-04-12 CA CA2758321A patent/CA2758321A1/en not_active Abandoned
- 2010-04-12 RU RU2011146032/15A patent/RU2569056C2/ru not_active IP Right Cessation
- 2010-04-12 US US12/758,631 patent/US8404711B2/en not_active Expired - Fee Related
- 2010-04-12 MX MX2011010782A patent/MX2011010782A/es active IP Right Grant
- 2010-04-12 BR BRPI1013777A patent/BRPI1013777A8/pt not_active IP Right Cessation
- 2010-04-12 CN CN2010800164976A patent/CN102395371A/zh active Pending
- 2010-04-12 NO NO10713790A patent/NO2419104T3/no unknown
- 2010-04-12 PL PL10713790T patent/PL2419104T3/pl unknown
- 2010-04-12 DK DK10713790.3T patent/DK2419104T3/en active
- 2010-04-12 SM SM20180036T patent/SMT201800036T1/it unknown
- 2010-04-12 PT PT107137903T patent/PT2419104T/pt unknown
- 2010-04-12 CN CN201610257689.5A patent/CN105832735A/zh active Pending
- 2010-04-12 EP EP10713790.3A patent/EP2419104B1/en active Active
- 2010-04-12 KR KR1020117026729A patent/KR20120017421A/ko not_active Ceased
- 2010-04-12 SI SI201031632T patent/SI2419104T1/en unknown
- 2010-04-12 AU AU2010236734A patent/AU2010236734B2/en not_active Ceased
- 2010-04-12 HU HUE10713790A patent/HUE038141T2/hu unknown
- 2010-04-12 LT LTEP10713790.3T patent/LT2419104T/lt unknown
- 2010-04-12 ES ES10713790.3T patent/ES2654930T3/es active Active
- 2010-04-12 HR HRP20180018TT patent/HRP20180018T1/hr unknown
- 2010-04-12 WO PCT/US2010/030760 patent/WO2010120695A2/en not_active Ceased
- 2010-04-12 JP JP2012504924A patent/JP2012523437A/ja active Pending
-
2011
- 2011-10-10 IL IL215660A patent/IL215660A0/en unknown
- 2011-10-12 ZA ZA2011/07490A patent/ZA201107490B/en unknown
-
2013
- 2013-02-20 US US13/771,685 patent/US20140057939A1/en not_active Abandoned
-
2018
- 2018-01-19 CY CY20181100069T patent/CY1119800T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006108127A2 (en) * | 2005-04-06 | 2006-10-12 | Theravance, Inc. | Crystalline form of a quinolinone-carboxamide compound |
Also Published As
| Publication number | Publication date |
|---|---|
| PT2419104T (pt) | 2018-01-31 |
| RU2011146032A (ru) | 2013-05-20 |
| KR20120017421A (ko) | 2012-02-28 |
| EP2419104B1 (en) | 2017-11-08 |
| IL215660A0 (en) | 2012-01-31 |
| WO2010120695A3 (en) | 2010-12-02 |
| JP2012523437A (ja) | 2012-10-04 |
| US20140057939A1 (en) | 2014-02-27 |
| DK2419104T3 (en) | 2018-02-05 |
| BRPI1013777A8 (pt) | 2017-09-19 |
| US20100261752A1 (en) | 2010-10-14 |
| CA2758321A1 (en) | 2010-10-21 |
| SI2419104T1 (en) | 2018-03-30 |
| AU2010236734A8 (en) | 2012-02-16 |
| NO2419104T3 (https=) | 2018-04-07 |
| CN105832735A (zh) | 2016-08-10 |
| US8404711B2 (en) | 2013-03-26 |
| CN102395371A (zh) | 2012-03-28 |
| MX2011010782A (es) | 2012-01-20 |
| ES2654930T3 (es) | 2018-02-15 |
| LT2419104T (lt) | 2018-02-12 |
| WO2010120695A2 (en) | 2010-10-21 |
| ZA201107490B (en) | 2012-06-27 |
| HRP20180018T1 (hr) | 2018-02-09 |
| RU2569056C2 (ru) | 2015-11-20 |
| SMT201800036T1 (it) | 2018-03-08 |
| BRPI1013777A2 (pt) | 2016-04-05 |
| AU2010236734A1 (en) | 2011-11-03 |
| PL2419104T3 (pl) | 2018-04-30 |
| EP2419104A2 (en) | 2012-02-22 |
| HUE038141T2 (hu) | 2018-10-29 |
| CY1119800T1 (el) | 2018-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2010236734B2 (en) | 5-HT4 receptor agonist compounds for treatment of cognitive disorders | |
| JP6050115B2 (ja) | アルツハイマー型認知症を治療するための方法及び組成物 | |
| AU2009229372C1 (en) | Use and composition for treating dementia | |
| KR102559354B1 (ko) | 치매 치료 | |
| US6117890A (en) | Method for treating bipolar disorder | |
| HK1165722A (en) | Combinations of 5-ht4 receptor agonists and acetylcholinesterase inhibitors for treatment of cognitive disorders | |
| HK1165722B (en) | Combinations of 5-ht4 receptor agonists and acetylcholinesterase inhibitors for treatment of cognitive disorders | |
| WO1998005324A1 (en) | Method for treating bipolar disorder | |
| WO2022066694A1 (en) | Pharmaceutical combination for the treatment of human hypocholinergic disorders | |
| AU2016231489B2 (en) | Composition for treating dementia | |
| AU2016231493B2 (en) | Composition for treating dementia | |
| AU2014277685C1 (en) | Composition for treating dementia | |
| HK1239557A1 (en) | Combination of a nspacha (peripheral anticholinergic agent) like solifenacin and an achei (acetyl choline esterase inhibitor) like donepezil for treating dementia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TH | Corrigenda |
Free format text: IN VOL 25, NO 43, PAGE(S) 5428 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME THERAVANCE, INC., APPLICATION NO. 2010236734, UNDER INID (54) CORRECT THE TITLE TO 5-HT4 RECEPTOR AGONIST COMPOUNDS FOR TREATMENT OF COGNITIVE DISORDERS |
|
| PC1 | Assignment before grant (sect. 113) |
Owner name: THERAVANCE BIOPHARMA R&D IP, LLC Free format text: FORMER APPLICANT(S): THERAVANCE, INC. |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |